-

Bayer Wins Third Consecutive Trial Victory

Company has now won 13 of last 19 cases where judgments were entered at trial

WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer won its third consecutive trial victory when a jury reached a defense verdict in its most recent trial – the Kline Roundup™ product liability trial – before Judge Ann Butchart in Philadelphia.

Separately, Plaintiffs voluntarily dismissed with prejudice the Meyer case which was at trial in the Superior Court of California for Sonoma County. These follow the defense verdict in Cody in Conway County, Arkansas, as well as a mistrial in Cloud in Delaware state court, both occurring late last week.

Bayer has now won three consecutive victories at trial, and 13 of the last 19 cases where judgments were entered at trial.

“Validating the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence, Bayer has now won three consecutive victories at trial and 13 of the last 19 cases where judgments were entered at trial,” the company said. “In these cases, the plaintiffs could not prove that Roundup™ was the cause of the injuries alleged in these cases, consistent with this science.”

The unanimous Kline verdict is the first to follow significant rulings in the Philadelphia litigation clarifying which scientific and regulatory conclusions could be admitted, a much-disputed issue in prior trials.

“While we have great sympathy for anyone who suffers a loss or injury, science proves that Roundup™ is not carcinogenic,” said the company. “We continue to stand behind the safety of Roundup™ and will confidently defend the safety of our products and our good faith actions in any future litigation.”

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Bayer


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Bayer

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based o...

Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause.1 Through the partnership, Hart will share her personal experience with moderate to severe hot flashes due to menopause to help women recognize their symptoms and to encourage more proactive treatmen...

U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete...
Back to Newsroom